Table 5B Progression-free survival in patients with hepatocellular carcinoma enrolled in part 2 and treated at the RP2D

From: Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

Patient number

Progression-free survival, days

03–036

336

03–039

34

03–041

52

03–043

133

03–044

277a

  1. Abbreviation: RP2D=recommended phase II dose.
  2. aCensored observation.
Back to article page